Navigation Links
Cardiogenesis Announces Successful Symposium at the Transcatheter Cardiovascular Therapeutics (TCT) Meeting
Date:9/23/2009

IRVINE, Calif., Sept. 23 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP), a market leader in laser transmyocardial revascularization (TMR), today announced that it sponsored an educational symposium yesterday in conjunction with the 21st Annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Francisco.

The symposium, titled "Opportunities in Refractory Angina" was attended by over 80 cardiologists. The Program Chairman was Christopher J. White MD, Chairman, Department of Cardiovascular Disease Ochsner Clinic, and the faculty included Timothy D. Henry MD Director of Research Minneapolis Heart Institute, Marvin J. Slepian MD, Clinical Professor of Medicine University of Arizona and Michael J. Bates, Cardiothoracic Surgeon Ochsner Clinic.

"The challenge of effectively treating patients with refractory angina is that these patients may be followed by any one of thousands of cardiologists, internists, general practitioners, and at times heart failure specialists. The TCT program was designed to update the cardiology community on clinical options and in the case of Dr. Henry's presentation, effective strategies for cardiologists to build a refractory angina practice" stated Paul J. McCormick Executive Chairman Cardiogenesis. He continued "we believe we have a solid opportunity for our current technology by working with the cardiology community to develop patient referrals. Considering the early clinical results achieved, we believe that opportunity can significantly increase with the addition of various biologics. We have a meeting scheduled with the FDA on October 21 in Rockville, MD to discuss our IDE submission for our PHOENIX(R) Combination Delivery System."

About Cardiogenesis Corporation

Cardiogenesis is a medical device company specializing in the therapies for the treatment of chronic cardiac ischemia. The company's market leading FDA approved Holmium:YAG laser system and disposable fiber-optic accessories are used to perform a surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease.

For more information on the company and its products, please visit the Cardiogenesis company website at http://www.cardiogenesis.com or the direct to patient website at http://www.heartofnewlife.com.

With the exception of historical information, the statements set forth above include forward-looking statements. Any forward-looking statements in this news release related to the possible effectiveness of the company's PHOENIX delivery system or other technologies and the planned clinical trials, are based on current expectations and beliefs and are subject to numerous risks and uncertainties, which are discussed in the "Risk Factors" section of the company's Annual Report on Form 10-K for the year ended December 31, 2008 and the company's other recent SEC filings. The company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.


'/>"/>
SOURCE Cardiogenesis Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiogenesis Receives FDA Approval for PEARL 5.0 Robotic Hand Piece
2. Cardiogenesis Corporation to Report 2007 Fourth Quarter and Year-End Results on March 4th
3. Cardiogenesis Corporation Reports Delay in Earnings Release and Conference Call
4. Cardiogenesis Corporation Announces Rescheduled Fourth Quarter and Full Year 2007 Earnings Release
5. Cardiogenesis Corporation to Report 2008 First Quarter Results on May 15th
6. Cardiogenesis Reports First Quarter 2008 Results
7. Cardiogenesis Announces Preliminary Results Combining TMR + Platelet Rich Plasma (PRP)
8. Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C.
9. Cardiogenesis Corporation to Report Third Quarter 2008 Results on November 13th
10. Cardiogenesis Announces Successful Educational Symposium at Society of Thoracic Surgeons Meeting in San Francisco
11. Cardiogenesis Corporation to Report 2008 Fourth Quarter and Year-End Results on March 31st
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... ... A man who has struggled to quit smoking, a man who has struggled with hair ... solutions to his problems – and he did. Now Nabat, a serial entrepreneur featured as ... breakthrough inventions to the world and better people's lives. His own experience with nicotine addiction ...
(Date:2/8/2016)... ... 08, 2016 , ... Steve Helwig & Associates Insurance & Financial, serving the ... has teamed up with Citizens Opposed to Domestic Abuse in support of its efforts ... all those victimized by the fear of violence in their own homes, donations may ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... announced today that nominations will be accepted February 8, 2016 through May ... , Awards include the Information Security Executive® of the Year, which recognizes ...
(Date:2/8/2016)... ... February 08, 2016 , ... Discover the Rocky Mountain region’s longest running and ... companies. Attendees also get to see the most incredible gardens and home improvement ... , at the Colorado Convention Center - 700 14th St. Denver CO, is an ...
(Date:2/8/2016)... ... February 08, 2016 , ... Joshua ... on how healthcare companies can use newly released government data on populations and ... population and intervene and capture the value they create to succeed in new ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Company, Inc. (NYSE MKT: AXN) today announced that for the ... the Company achieved revenue of $8,195,839, a 27% improvement on ... 2015. --> --> The ... $2,068,635, or $.03 per share, up 265% from the net ... of fiscal year 2015. Gross margin for the three months ...
(Date:2/8/2016)...  HemaFlo Therapeutics, Inc. announced today that the United States ... 9,119,880 covering the use of NephroFlow to treat acute kidney ... founder, said, "We are pleased to secure our rights to ... , PhD, HemaFlo,s founder, said, "We are pleased to secure ... Dale Peterson , PhD, HemaFlo,s founder, said, "We ...
(Date:2/8/2016)... Calif. , Feb. 8, 2016  Sangamo ... in therapeutic genome editing, announced that the U.S. ... Company,s Investigational New Drug (IND) application for SB-318, ... life-long therapy for Mucopolysaccharidosis Type I (MPS I). ... enables Sangamo to initiate a Phase 1/2 clinical ...
Breaking Medicine Technology: